000904371 001__ 904371
000904371 005__ 20230123101900.0
000904371 0247_ $$2doi$$a10.1002/mds.28624
000904371 0247_ $$2ISSN$$a0885-3185
000904371 0247_ $$2ISSN$$a1531-8257
000904371 0247_ $$2Handle$$a2128/32246
000904371 0247_ $$2pmid$$a33951244
000904371 0247_ $$2WOS$$aWOS:000647195800001
000904371 037__ $$aFZJ-2021-05941
000904371 082__ $$a610
000904371 1001_ $$0P:(DE-HGF)0$$aPalleis, Carla$$b0
000904371 245__ $$aCortical [18F]PI‐2620 Binding Differentiates Corticobasal Syndrome Subtypes
000904371 260__ $$aNew York, NY$$bWiley$$c2021
000904371 3367_ $$2DRIVER$$aarticle
000904371 3367_ $$2DataCite$$aOutput Types/Journal article
000904371 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1667372222_15986
000904371 3367_ $$2BibTeX$$aARTICLE
000904371 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000904371 3367_ $$00$$2EndNote$$aJournal Article
000904371 520__ $$aBackground: Corticobasal syndrome is associated with cerebral protein aggregates composed of 4-repeat (~50% of cases) or mixed 3-repeat/4-repeat tau isoforms (~25% of cases) or nontauopathies (~25% of cases).Objectives: The aim of this single-center study was to investigate the diagnostic value of the tau PET-ligand [18 F]PI-2620 in patients with corticobasal syndrome.Methods: Forty-five patients (71.5 ± 7.6 years) with corticobasal syndrome and 14 age-matched healthy controls underwent [18 F]PI-2620-PET. Beta-amyloid status was determined by cerebral β-amyloid PET and/or CSF analysis. Subcortical and cortical [18 F]PI-2620 binding was quantitatively and visually compared between β-amyloid-positive and -negative patients and controls. Regional [18 F]PI-2620 binding was correlated with clinical and demographic data.Results: Twenty-four percent (11 of 45) were β-amyloid-positive. Significantly elevated [18 F]PI-2620 distribution volume ratios were observed in both β-amyloid-positive and β-amyloid-negative patients versus controls in the dorsolateral prefrontal cortex and basal ganglia. Cortical [18 F]PI-2620 PET positivity was distinctly higher in β-amyloid-positive compared with β-amyloid-negative patients with pronounced involvement of the dorsolateral prefrontal cortex. Semiquantitative analysis of [18 F]PI-2620 PET revealed a sensitivity of 91% for β-amyloid-positive and of 65% for β-amyloid-negative cases, which is in excellent agreement with prior clinicopathological data. Regardless of β-amyloid status, hemispheric lateralization of [18 F]PI-2620 signal reflected contralateral predominance of clinical disease severity.Conclusions: Our data indicate a value of [18 F]PI-2620 for evaluating corticobasal syndrome, providing quantitatively and regionally distinct signals in β-amyloid-positive as well as β-amyloid-negative corticobasal syndrome. In corticobasal syndrome, [18 F]PI-2620 may potentially serve for a differential diagnosis and for monitoring disease progression. © 2021 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.Keywords: Alzheimer's disease; PET; corticobasal syndrome; four-repeat tauopathies; tau.
000904371 536__ $$0G:(DE-HGF)POF4-5253$$a5253 - Neuroimaging (POF4-525)$$cPOF4-525$$fPOF IV$$x0
000904371 588__ $$aDataset connected to CrossRef, Journals: juser.fz-juelich.de
000904371 7001_ $$0P:(DE-HGF)0$$aBrendel, Matthias$$b1
000904371 7001_ $$0P:(DE-HGF)0$$aFinze, Anika$$b2
000904371 7001_ $$0P:(DE-HGF)0$$aWeidinger, Endy$$b3
000904371 7001_ $$0P:(DE-HGF)0$$aBötzel, Kai$$b4
000904371 7001_ $$0P:(DE-HGF)0$$aDanek, Adrian$$b5
000904371 7001_ $$0P:(DE-HGF)0$$aBeyer, Leonie$$b6
000904371 7001_ $$0P:(DE-HGF)0$$aNitschmann, Alexander$$b7
000904371 7001_ $$0P:(DE-HGF)0$$aKern, Maike$$b8
000904371 7001_ $$0P:(DE-HGF)0$$aBiechele, Gloria$$b9
000904371 7001_ $$0P:(DE-HGF)0$$aRauchmann, Boris-Stephan$$b10
000904371 7001_ $$0P:(DE-HGF)0$$aHäckert, Jan$$b11
000904371 7001_ $$0P:(DE-HGF)0$$aHöllerhage, Matthias$$b12
000904371 7001_ $$0P:(DE-HGF)0$$aStephens, Andrew W.$$b13
000904371 7001_ $$0P:(DE-Juel1)177611$$aDrzezga, Alexander$$b14
000904371 7001_ $$0P:(DE-HGF)0$$aEimeren, Thilo$$b15
000904371 7001_ $$0P:(DE-HGF)0$$aVillemagne, Victor L.$$b16
000904371 7001_ $$0P:(DE-HGF)0$$aSchildan, Andreas$$b17
000904371 7001_ $$0P:(DE-HGF)0$$aBarthel, Henryk$$b18
000904371 7001_ $$0P:(DE-HGF)0$$aPatt, Marianne$$b19
000904371 7001_ $$0P:(DE-HGF)0$$aSabri, Osama$$b20
000904371 7001_ $$0P:(DE-HGF)0$$aBartenstein, Peter$$b21
000904371 7001_ $$0P:(DE-HGF)0$$aPerneczky, Robert$$b22
000904371 7001_ $$0P:(DE-HGF)0$$aHaass, Christian$$b23
000904371 7001_ $$0P:(DE-HGF)0$$aLevin, Johannes$$b24$$eCorresponding author
000904371 7001_ $$0P:(DE-HGF)0$$aHöglinger, Günter U.$$b25$$eCorresponding author
000904371 773__ $$0PERI:(DE-600)2041249-6$$a10.1002/mds.28624$$gVol. 36, no. 9, p. 2104 - 2115$$n9$$p2104 - 2115$$tMovement disorders$$v36$$x0885-3185$$y2021
000904371 8564_ $$uhttps://juser.fz-juelich.de/record/904371/files/Movement%20Disorders%20-%202021%20-%20Palleis%20-%20Cortical%2018F%20PI%25u20102620%20Binding%20Differentiates%20Corticobasal%20Syndrome%20Subtypes.pdf$$yOpenAccess
000904371 909CO $$ooai:juser.fz-juelich.de:904371$$pdnbdelivery$$pdriver$$pVDB$$popen_access$$popenaire
000904371 9101_ $$0I:(DE-HGF)0$$6P:(DE-HGF)0$$a  Department of Neurology, Ludwig-Maximilians-University, Munich, Germany$$b0
000904371 9101_ $$0I:(DE-HGF)0$$6P:(DE-HGF)0$$a German Center for Neurodegenerative Diseases (DZNE), Munich, Germany$$b0
000904371 9101_ $$0I:(DE-HGF)0$$6P:(DE-HGF)0$$a Department of Nuclear Medicine, Ludwig-Maximilians-University, Munich, Germany$$b1
000904371 9101_ $$0I:(DE-HGF)0$$6P:(DE-HGF)0$$a Munich Cluster for Systems Neurology (SyNergy), Munich, Germany$$b1
000904371 9101_ $$0I:(DE-HGF)0$$6P:(DE-HGF)0$$a Department of Nuclear Medicine, Ludwig-Maximilians-University, Munich, Germany$$b2
000904371 9101_ $$0I:(DE-HGF)0$$6P:(DE-HGF)0$$a Department of Neurology, Ludwig-Maximilians-University, Munich, Germany$$b3
000904371 9101_ $$0I:(DE-HGF)0$$6P:(DE-HGF)0$$a German Center for Neurodegenerative Diseases (DZNE), Munich, Germany$$b3
000904371 9101_ $$0I:(DE-HGF)0$$6P:(DE-HGF)0$$a Department of Neurology, Ludwig-Maximilians-University, Munich, Germany$$b4
000904371 9101_ $$0I:(DE-HGF)0$$6P:(DE-HGF)0$$a Department of Neurology, Ludwig-Maximilians-University, Munich, Germany$$b5
000904371 9101_ $$0I:(DE-HGF)0$$6P:(DE-HGF)0$$a Department of Nuclear Medicine, Ludwig-Maximilians-University, Munich, Germany$$b6
000904371 9101_ $$0I:(DE-HGF)0$$6P:(DE-HGF)0$$a Department of Nuclear Medicine, Ludwig-Maximilians-University, Munich, Germany$$b7
000904371 9101_ $$0I:(DE-HGF)0$$6P:(DE-HGF)0$$a Department of Nuclear Medicine, Ludwig-Maximilians-University, Munich, Germany$$b8
000904371 9101_ $$0I:(DE-HGF)0$$6P:(DE-HGF)0$$a Department of Nuclear Medicine, Ludwig-Maximilians-University, Munich, Germany$$b9
000904371 9101_ $$0I:(DE-HGF)0$$6P:(DE-HGF)0$$a Department of Radiology, Ludwig-Maximilians-University, Munich, Germany$$b10
000904371 9101_ $$0I:(DE-HGF)0$$6P:(DE-HGF)0$$a Department of Psychiatry and Psychotherapy, Ludwig-Maximilians-University, Munich, Germany$$b10
000904371 9101_ $$0I:(DE-HGF)0$$6P:(DE-HGF)0$$a Department of Psychiatry and Psychotherapy, Ludwig-Maximilians-University, Munich, Germany$$b11
000904371 9101_ $$0I:(DE-HGF)0$$6P:(DE-HGF)0$$a Department of Neurology, Hannover Medical School, Hannover, Germany$$b12
000904371 9101_ $$0I:(DE-HGF)0$$6P:(DE-HGF)0$$a Department of Neurology, Hannover Medical School, Hannover, Germany$$b13
000904371 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)177611$$aForschungszentrum Jülich$$b14$$kFZJ
000904371 9101_ $$0I:(DE-HGF)0$$6P:(DE-Juel1)177611$$a Department of Nuclear Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany$$b14
000904371 9101_ $$0I:(DE-HGF)0$$6P:(DE-Juel1)177611$$a German Center for Neurodegenerative Diseases (DZNE), Bonn-Cologne, Germany$$b14
000904371 9101_ $$0I:(DE-HGF)0$$6P:(DE-HGF)0$$a German Center for Neurodegenerative Diseases (DZNE), Bonn-Cologne, Germany$$b15
000904371 9101_ $$0I:(DE-HGF)0$$6P:(DE-HGF)0$$a  Department of Nuclear Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany$$b15
000904371 9101_ $$0I:(DE-HGF)0$$6P:(DE-HGF)0$$a Department of Neurology, University Hospital Cologne, Cologne, Germany$$b15
000904371 9101_ $$0I:(DE-HGF)0$$6P:(DE-HGF)0$$a Department of Psychiatry, The University of Pittsburgh, Pittsburgh, Pennsylvania, USA$$b16
000904371 9101_ $$0I:(DE-HGF)0$$6P:(DE-HGF)0$$a Department of Nuclear Medicine, University of Leipzig, Leipzig, Germany$$b17
000904371 9101_ $$0I:(DE-HGF)0$$6P:(DE-HGF)0$$a Department of Nuclear Medicine, University of Leipzig, Leipzig, Germany$$b18
000904371 9101_ $$0I:(DE-HGF)0$$6P:(DE-HGF)0$$a Department of Nuclear Medicine, University of Leipzig, Leipzig, Germany$$b19
000904371 9101_ $$0I:(DE-HGF)0$$6P:(DE-HGF)0$$a Department of Nuclear Medicine, University of Leipzig, Leipzig, Germany$$b20
000904371 9101_ $$0I:(DE-HGF)0$$6P:(DE-HGF)0$$a Department of Nuclear Medicine, Ludwig-Maximilians-University, Munich, Germany$$b21
000904371 9101_ $$0I:(DE-HGF)0$$6P:(DE-HGF)0$$a Munich Cluster for Systems Neurology (SyNergy), Munich, Germany$$b21
000904371 9101_ $$0I:(DE-HGF)0$$6P:(DE-HGF)0$$a German Imaging Initiative for Tauopathies (GII4T)$$b21
000904371 9101_ $$0I:(DE-HGF)0$$6P:(DE-HGF)0$$a  German Center for Neurodegenerative Diseases (DZNE), Munich, Germany$$b22
000904371 9101_ $$0I:(DE-HGF)0$$6P:(DE-HGF)0$$a Munich Cluster for Systems Neurology (SyNergy), Munich, Germany$$b22
000904371 9101_ $$0I:(DE-HGF)0$$6P:(DE-HGF)0$$a  Department of Psychiatry and Psychotherapy, Ludwig-Maximilians-University, Munich, Germany$$b22
000904371 9101_ $$0I:(DE-HGF)0$$6P:(DE-HGF)0$$a Ageing Epidemiology (AGE) Research Unit, School of Public Health, Imperial College, London, United Kingdom$$b22
000904371 9101_ $$0I:(DE-HGF)0$$6P:(DE-HGF)0$$a German Center for Neurodegenerative Diseases (DZNE), Munich, Germany$$b23
000904371 9101_ $$0I:(DE-HGF)0$$6P:(DE-HGF)0$$a Munich Cluster for Systems Neurology (SyNergy), Munich, Germany$$b23
000904371 9101_ $$0I:(DE-HGF)0$$6P:(DE-HGF)0$$a  Chair of Metabolic Biochemistry, Biomedical Center (BMC), Faculty of Medicine, Ludwig-Maximilians-University, Munich, Germany$$b23
000904371 9101_ $$0I:(DE-HGF)0$$6P:(DE-HGF)0$$a Department of Neurology, Ludwig-Maximilians-University, Munich, Germany$$b24
000904371 9101_ $$0I:(DE-HGF)0$$6P:(DE-HGF)0$$a German Center for Neurodegenerative Diseases (DZNE), Munich, Germany$$b24
000904371 9101_ $$0I:(DE-HGF)0$$6P:(DE-HGF)0$$a Munich Cluster for Systems Neurology (SyNergy), Munich, Germany$$b24
000904371 9101_ $$0I:(DE-HGF)0$$6P:(DE-HGF)0$$a  German Center for Neurodegenerative Diseases (DZNE), Munich, Germany$$b25
000904371 9101_ $$0I:(DE-HGF)0$$6P:(DE-HGF)0$$a Munich Cluster for Systems Neurology (SyNergy), Munich, Germany$$b25
000904371 9101_ $$0I:(DE-HGF)0$$6P:(DE-HGF)0$$a Department of Neurology, Hannover Medical School, Hannover, Germany$$b25
000904371 9131_ $$0G:(DE-HGF)POF4-525$$1G:(DE-HGF)POF4-520$$2G:(DE-HGF)POF4-500$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$9G:(DE-HGF)POF4-5253$$aDE-HGF$$bKey Technologies$$lNatural, Artificial and Cognitive Information Processing$$vDecoding Brain Organization and Dysfunction$$x0
000904371 9141_ $$y2022
000904371 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2021-01-30
000904371 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-01-30
000904371 915__ $$0LIC:(DE-HGF)CCBY4$$2HGFVOC$$aCreative Commons Attribution CC BY 4.0
000904371 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2021-01-30
000904371 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bMOVEMENT DISORD : 2019$$d2021-01-30
000904371 915__ $$0StatID:(DE-HGF)3001$$2StatID$$aDEAL Wiley$$d2021-01-30$$wger
000904371 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2021-01-30
000904371 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-01-30
000904371 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2021-01-30
000904371 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000904371 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2021-01-30
000904371 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bMOVEMENT DISORD : 2019$$d2021-01-30
000904371 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2021-01-30
000904371 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2021-01-30
000904371 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2021-01-30$$wger
000904371 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2021-01-30
000904371 920__ $$lyes
000904371 9201_ $$0I:(DE-Juel1)INM-2-20090406$$kINM-2$$lMolekulare Organisation des Gehirns$$x0
000904371 980__ $$ajournal
000904371 980__ $$aVDB
000904371 980__ $$aUNRESTRICTED
000904371 980__ $$aI:(DE-Juel1)INM-2-20090406
000904371 9801_ $$aFullTexts